Onco-Innovations Announces Private Placement
Onco-Innovations (OTCQB:ONNVF) has announced a non-brokered private placement of up to 400,000 units at $1.50 per unit, aiming to raise gross proceeds of up to $600,000. Each unit includes one common share and one warrant, with each warrant allowing the purchase of one share at $1.60 for 36 months.
The private placement is expected to close around April 25, 2025, subject to regulatory approvals. Securities will have a four-month and one-day hold period. The company plans to use the proceeds for general corporate and working capital purposes, including operational and R&D objectives.
Onco-Innovations is a Canadian company focused on cancer research and treatment, holding an exclusive worldwide license for patented technology targeting solid tumors.
Onco-Innovations (OTCQB:ONNVF) ha annunciato un collocamento privato non mediato fino a 400.000 unità a $1,50 per unità, con l'obiettivo di raccogliere proventi lordi fino a $600.000. Ogni unità include un'azione ordinaria e un warrant, con ogni warrant che consente l'acquisto di un'azione a $1,60 per 36 mesi.
Il collocamento privato dovrebbe concludersi intorno al 25 aprile 2025, soggetto all'approvazione delle autorità regolatorie. I titoli avranno un periodo di blocco di quattro mesi e un giorno. La società prevede di utilizzare i proventi per scopi generali aziendali e di capitale circolante, inclusi obiettivi operativi e di ricerca e sviluppo.
Onco-Innovations è una società canadese focalizzata sulla ricerca e il trattamento del cancro, detentrice di una licenza esclusiva mondiale per una tecnologia brevettata mirata ai tumori solidi.
Onco-Innovations (OTCQB:ONNVF) ha anunciado una colocación privada sin intermediarios de hasta 400,000 unidades a $1.50 por unidad, con el objetivo de recaudar ingresos brutos de hasta $600,000. Cada unidad incluye una acción común y un warrant, siendo cada warrant la opción de comprar una acción a $1.60 durante 36 meses.
Se espera que la colocación privada cierre alrededor del 25 de abril de 2025, sujeta a aprobaciones regulatorias. Los valores tendrán un período de retención de cuatro meses y un día. La compañía planea usar los ingresos para propósitos corporativos generales y capital de trabajo, incluyendo objetivos operativos y de I+D.
Onco-Innovations es una empresa canadiense enfocada en la investigación y tratamiento del cáncer, que posee una licencia exclusiva mundial para tecnología patentada dirigida a tumores sólidos.
Onco-Innovations (OTCQB:ONNVF)는 단위당 $1.50에 최대 400,000단위의 비중개 사모 발행을 발표했으며, 총 최대 $600,000의 자금 조달을 목표로 하고 있습니다. 각 단위는 보통주 1주와 워런트 1주를 포함하며, 워런트 1주는 36개월 동안 주당 $1.60에 주식을 구매할 수 있는 권리를 제공합니다.
사모 발행은 규제 승인에 따라 2025년 4월 25일경 마감될 예정입니다. 증권은 4개월 1일의 보호예수 기간이 적용됩니다. 회사는 조달 자금을 일반 기업 운영 및 운전자본 용도, 운영 및 연구개발 목표에 사용할 계획입니다.
Onco-Innovations는 고형암을 타겟으로 한 특허 기술에 대한 전 세계 독점 라이선스를 보유한 캐나다 기반의 암 연구 및 치료 전문 기업입니다.
Onco-Innovations (OTCQB:ONNVF) a annoncé un placement privé sans intermédiaire pouvant atteindre 400 000 unités à 1,50 $ par unité, visant à lever jusqu'à 600 000 $ de produits bruts. Chaque unité comprend une action ordinaire et un bon de souscription, chaque bon permettant l'achat d'une action à 1,60 $ pendant 36 mois.
Le placement privé devrait se clôturer aux alentours du 25 avril 2025, sous réserve des approbations réglementaires. Les titres seront soumis à une période de blocage de quatre mois et un jour. La société prévoit d’utiliser les fonds pour des besoins généraux d’entreprise et de fonds de roulement, y compris des objectifs opérationnels et de R&D.
Onco-Innovations est une société canadienne spécialisée dans la recherche et le traitement du cancer, détenant une licence mondiale exclusive pour une technologie brevetée ciblant les tumeurs solides.
Onco-Innovations (OTCQB:ONNVF) hat eine nicht vermittelte Privatplatzierung von bis zu 400.000 Einheiten zu je 1,50 $ angekündigt, mit dem Ziel, Bruttoerlöse von bis zu 600.000 $ zu erzielen. Jede Einheit umfasst eine Stammaktie und einen Warrant, wobei jeder Warrant den Kauf einer Aktie zu 1,60 $ für 36 Monate ermöglicht.
Die Privatplatzierung soll voraussichtlich um den 25. April 2025 abgeschlossen werden, vorbehaltlich behördlicher Genehmigungen. Die Wertpapiere unterliegen einer Haltefrist von vier Monaten und einem Tag. Das Unternehmen plant, die Erlöse für allgemeine Unternehmenszwecke und Betriebskapital, einschließlich operativer und F&E-Ziele, zu verwenden.
Onco-Innovations ist ein kanadisches Unternehmen, das sich auf Krebsforschung und -behandlung spezialisiert hat und eine exklusive weltweite Lizenz für patentierte Technologie zur Bekämpfung von soliden Tumoren besitzt.
- Company holds exclusive worldwide license for solid tumor treatment technology
- Potential shareholder dilution through private placement of 400,000 units
- Additional dilution possible through warrant exercise at $1.60 per share
Not for distribution to United States wire services or for dissemination in the United States
VANCOUVER, BC / ACCESS Newswire / April 16, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") of up to 400,000 units of the Company (the "Units") at a price of
Each Unit shall consist of one common share (each a "Share") and one common share purchase warrant (each whole warrant, a "Warrant"), with each (whole) Warrant entitling the holder to purchase one Share at an exercise price of
Closing of the Private Placement is anticipated to occur on or about April 25, 2025, and is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws.
The Company intends to use the proceeds of the Private Placement for general corporate and working capital purposes, including in pursuit of the Company's operational and research and development objectives.
The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy" Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated closing date thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to complete the Private Placement as contemplated, or at all, that the anticipated proceeds may be lower than expected, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
What are the terms of Onco-Innovations (ONNVF) private placement announced in April 2025?
How much capital is ONNVF seeking to raise through its April 2025 private placement?
When will the ONNVF private placement close?
How will Onco-Innovations use the proceeds from its 2025 private placement?
